Diabetes, Vol 45, Issue 10 1427-1430, Copyright © 1996 by American Diabetes Association

ARTICLES

Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes

E Bjork, C Berne, O Kampe, L Wibell, P Oskarsson and FA Karlsson
Department of Medicine, University Hospital, Uppsala, Sweden.

Twenty islet cell antibody (ICA)-positive patients, aged 19-38 years, with IDDM were randomized at onset to treatment with either diazoxide, a K+ channel opener that inhibits the release of insulin, or placebo for 3 months, in addition to multiple insulin injection therapy. The patients who were given diazoxide displayed higher residual insulin secretion than the placebo group after 1 year (basal C-peptide level, 0.40 +/- 0.04 vs. 0.25 +/- 0.04 [mean +/- SE] nmol/l; P < 0.021) and at an 18-month follow-up (0.37 +/- 0.06 vs. 0.20 +/- 0.01 nmol/l, P < 0.033). Metabolic control did not differ between the two groups. During the course of the study, no differences in islet cell or GAD autoantibodies were detected between the two groups. The results of this study warrant further trials to explore the potential of inducing target cell rest in order to halt the loss of insulin-producing cells during the early course of the disease.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. Ng, Y. Kang, C. L. Elias, Y. He, H. Xie, J. B. Hansen, P. Wahl, and H. Y. Gaisano The Actions of a Novel Potent Islet {beta}-Cell Specific ATP-Sensitive K+ Channel Opener Can Be Modulated by Syntaxin-1A Acting on Sulfonylurea Receptor 1 Diabetes, August 1, 2007; 56(8): 2124 - 2134. [Abstract] [Full Text] [PDF]

				B. L. Wajchenberg {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment Endocr. Rev., April 1, 2007; 28(2): 187 - 218. [Abstract] [Full Text] [PDF]

				G. Stenstrom, A. Gottsater, E. Bakhtadze, B. Berger, and G. Sundkvist Latent Autoimmune Diabetes in Adults: Definition, Prevalence, {beta}-Cell Function, and Treatment Diabetes, December 1, 2005; 54(suppl_2): S68 - S72. [Abstract] [Full Text] [PDF]

				M. Y. Donath, J. A. Ehses, K. Maedler, D. M. Schumann, H. Ellingsgaard, E. Eppler, and M. Reinecke Mechanisms of {beta}-Cell Death in Type 2 Diabetes Diabetes, December 1, 2005; 54(suppl_2): S108 - S113. [Abstract] [Full Text] [PDF]

				M. E. Rabaglia, M. P. Gray-Keller, B. L. Frey, M. R. Shortreed, L. M. Smith, and A. D. Attie {alpha}-Ketoisocaproate-induced hypersecretion of insulin by islets from diabetes-susceptible mice Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E218 - E224. [Abstract] [Full Text] [PDF]

				L Zhao, Z Li, M Kullin, L A H Borg, and F A Karlsson Alterations in net glucose uptake and in the pancreatic B-cell GLUT2 transporter induced by diazoxide and by secretory stimuli J. Endocrinol., May 1, 2005; 185(2): 291 - 299. [Abstract] [Full Text] [PDF]

				E. Ortqvist, E. Bjork, M. Wallensteen, J. Ludvigsson, J. Aman, C. Johansson, G. Forsander, F. Lindgren, L. Berglund, M. Bengtsson, et al. Temporary Preservation of {beta}-Cell Function by Diazoxide Treatment in Childhood Type 1 Diabetes Diabetes Care, September 1, 2004; 27(9): 2191 - 2197. [Abstract] [Full Text] [PDF]

				P. Arkhammar, P. Wahl, B. Gerlach, T. Fremming, and J. B. Hansen Establishment and Application of in Vitro Membrane Potential Assays in Cell Lines with Endogenous or Recombinant Expression of ATP-Sensitive Potassium Channels (Kir6.2/SUR1) Using a Fluorescent Probe Kit J Biomol Screen, August 1, 2004; 9(5): 382 - 390. [Abstract] [PDF]

				K. Maedler, J. Storling, J. Sturis, R. A. Zuellig, G. A. Spinas, P. O.G. Arkhammar, T. Mandrup-Poulsen, and M. Y. Donath Glucose- and Interleukin-1{beta}-Induced {beta}-Cell Apoptosis Requires Ca2+ Influx and Extracellular Signal-Regulated Kinase (ERK) 1/2 Activation and Is Prevented by a Sulfonylurea Receptor 1/Inwardly Rectifying K+ Channel 6.2 (SUR/Kir6.2) Selective Potassium Channel Opener in Human Islets Diabetes, July 1, 2004; 53(7): 1706 - 1713. [Abstract] [Full Text] [PDF]

				K. Skak, C. F. Gotfredsen, D. Lundsgaard, J. B. Hansen, J. Sturis, and H. Markholst Improved {beta}-Cell Survival and Reduced Insulitis in a Type 1 Diabetic Rat Model After Treatment With a {beta}-Cell-Selective KATP Channel Opener Diabetes, April 1, 2004; 53(4): 1089 - 1095. [Abstract] [Full Text] [PDF]

				R. A. Ritzel, J. B. Hansen, J. D. Veldhuis, and P. C. Butler Induction of {beta}-Cell Rest by a Kir6.2/SUR1-Selective KATP-Channel Opener Preserves {beta}-Cell Insulin Stores and Insulin Secretion in Human Islets Cultured at High (11 mM) Glucose J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 795 - 805. [Abstract] [Full Text] [PDF]

				C. J. Greenbaum and L. C. Harrison Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes Diabetes, May 1, 2003; 52(5): 1059 - 1065. [Full Text] [PDF]

				K. E. Cosgrove, M.-H. Antoine, A. T. Lee, P. D. Barnes, P. de Tullio, P. Clayton, R. McCloy, P. De Lonlay, C. Nihoul-Fekete, J.-J. Robert, et al. BPDZ 154 Activates Adenosine 5'-Triphosphate-Sensitive Potassium Channels: In Vitro Studies Using Rodent Insulin-Secreting Cells and Islets Isolated from Patients with Hyperinsulinism J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4860 - 4868. [Abstract] [Full Text] [PDF]

				M. Dabrowski, F. M. Ashcroft, R. Ashfield, P. Lebrun, B. Pirotte, J. Egebjerg, J. Bondo Hansen, and P. Wahl The Novel Diazoxide Analog 3-Isopropylamino-7-Methoxy-4H-1,2,4-Benzothiadiazine 1,1-Dioxide Is a Selective Kir6.2/SUR1 Channel Opener Diabetes, June 1, 2002; 51(6): 1896 - 1906. [Abstract] [Full Text] [PDF]

				Z. Li, L. Zhao, S. Sandler, and F. A. Karlsson Expression of Pancreatic Islet MHC Class I, Insulin, and ICA 512 Tyrosine Phosphatase in Low-dose Streptozotocin-induced Diabetes in Mice J. Histochem. Cytochem., June 1, 2000; 48(6): 761 - 768. [Abstract] [Full Text]